Chapter 18: Design of Clinical In-Use Studies

  • Supriya GuptaEmail author
  • Amr Alaarg
  • Zhen Wu
  • Xiaofeng Lu
  • VivekKumar Garripelli
  • Hanmin Dong
  • Stephanie Sawilla
  • Bhargav Patel
  • Rudolf Schroeder
Part of the AAPS Advances in the Pharmaceutical Sciences Series book series (AAPS, volume 35)


For most parenteral biologics, in-use manipulation of drug product during the aseptic dose solution preparation and administration process is inevitable. The in-use product handling procedures, and compatibility issues with administration components used in the clinical setting, can potentially impact protein stability. Therefore, it becomes imperative to define dose solution preparation, handling, and administration procedures that ensure the quality of the product solution administered to patients.

The general clinical in-use study design recommendations and case studies presented in this chapter highlight the commonly observed stability issues for parenteral intravenous protein products. This information can be used by pharmaceutical scientists as a practical guide to design and execute robust in-use studies through the development cycle of a drug product candidate.


Biologics In-use testing Compounded sterile preparation Compatibility testing Pharmacy 


  1. 1.
    Gervasi V, Dall AR, Cullen S, Mccoy T, Vucen S, Crean A. Parenteral protein formulations: an overview of approved products within the European Union. Eur J Pharm Biopharm. 2018;131:8–24.CrossRefGoogle Scholar
  2. 2.
    Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13(9):655–72.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Geigert J. The challenge of CMC regulatory compliance for biopharmaceuticals and other biologics. 2nd ed: Springer; 2013.Google Scholar
  4. 4.
    ICH Harmonised Tripartite Guideline Q8 (R2) (2009): Pharmaceutical Development 1-18. Accessed November 26, 2018.
  5. 5.
    Guidance for Industry: dosage and administration section of labeling for human prescription drug and biological products — content and format. Accessed March 1, 2019.
  6. 6.
    FDA 21 CFR 201.57(c)(3): dosage and administration. Accessed March 1, 2019.
  7. 7.
    Regulation (EU) No. 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. Accessed March 7, 2019.
  8. 8.
    ICH Harmonised Tripartite Guideline Q1A(R2): Stability testing of new drug substances and products. Accessed February 12, 2019.
  9. 9.
    ICH Harmonised Tripartite Guideline Q5C: Stability testing of biotechnological/biological products. Accessed March 7, 2019.
  10. 10.
    EMA/CHMP/QWP/545525/2017: guideline on the requirements for the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials. Accessed November 28, 2018.
  11. 11.
    CPMP/QWP/2934/99: note for guidance on In-use stability testing of human medicinal products. Accessed March 7, 2019.
  12. 12.
    CPMP/QWP/159/96: note for guidance on maximum shelf-life for sterile products after first opening or following reconstitution. Accessed March 7, 2019.
  13. 13.
    WHO Technical Report Series, No. 953, 2009. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. Accessed March 7, 2019.
  14. 14.
    USP<797> Pharmaceutical Compounding-Sterile Preparations.Google Scholar
  15. 15.
    USP<51> Antimicrobial Effectiveness Testing.Google Scholar
  16. 16.
    Ricci MS, Frazier M, Moore J, Cromwell M, Galush WJ, Patel AR, Adler M, Altenburger U, Grauschopf U, Goldbach P, Fast JL, Kramer I, Mahler HC. In-use physicochemical and microbiological stability of biological parenteral products. Am J Health-Syst Pharm. 2015;72(5):396–407.CrossRefGoogle Scholar
  17. 17.
    Nejadnik MR, Randlph TW, Volkin DB, Schoneich C, Carpenter J, Crommelin Daan JA, Jiskoot W. Postproduction handling and administration of protein pharmaceuticals and potential instability issues. J Pharm Sci. 2018;107:2013–9.CrossRefGoogle Scholar
  18. 18.
    Vlieland ND, Gardarsdottir H, Bouvy ML, Egberts TC, van den Bemt BJ. The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. Rheumatology (Oxford). 2016;55(4):704–9.CrossRefGoogle Scholar
  19. 19.
    Jiskoot W, Nejadnik MR, Sediq AS. Potential issues with the handling of biologicals in a hospital. J Pharm Sci. 2017;106(6):1688–9.CrossRefGoogle Scholar
  20. 20.
    Sharma M, Cheung JK, Debbara A, Pertersen J. Intravenous admixture compatibility for sterile products: challenges and regulatory guidance. In: Kolhe P, Shah M, Rathore N, editors. Sterile product development – formulation, process and regulatory considerations, AAPS advances in the pharmaceutical sciences series 6. New York: Springer; 2013. p. 461–74.CrossRefGoogle Scholar
  21. 21.
    US Department of Health and Human Services and Drug Administration Guidance for Industry (2010): Dosage and adminitration section of labeling for human prescription drug and biological products—content and format. Accessed March 1, 2019.
  22. 22.
    Sedykh SE, Prinz VV, Buneva VN, Nevinsky GA. Bispecific antibodies: design, therapy, perspectives. Drug Des Devel Ther. 2018;12:195–208.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Reddi AS. Intravenous fluids: composition and indications. In book: Fluid, electrolyte and acid-base disorders. Springer. 2018. Accessed March 7, 2019.
  24. 24.
    Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185(2):129–88.CrossRefGoogle Scholar
  25. 25.
    Khan TA, Mahler HC, Kishore RS. Key interactions of surfactants in therapeutic protein formulations: a review. Eur J Pharm Biopharm. 2015;97(A):60–7.CrossRefGoogle Scholar
  26. 26.
    Minning M, Liu J, Li TS, Holcomb RE. Rational design of liquid formulations of proteins. Adv Protein Chem Struct Biol. 2018;112:1–59.CrossRefGoogle Scholar
  27. 27.
    Kamerzell TJ, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB. Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev. 2011;63(13):1118–59.CrossRefGoogle Scholar
  28. 28.
    Hawe A, Friess W. Formulation development for hydrophobic therapeutic proteins. Pharm Dev Technol. 2007;12(3):223–37.CrossRefGoogle Scholar
  29. 29.
    Avastin (bevacizumab)-FDA. Accessed March 8, 2019.
  30. 30.
    Herceptin-Product Information-Therapeutic Goods Administration. Accessed March 8, 2019. Springer, New York, NY.
  31. 31.
    Fischer S, Hoemschemeyer J, Mahler HC. Glycation during storage and administration of monoclonal antibody formulations. Eur J Pharm Biopharm. 2008;70(1):42–50.CrossRefGoogle Scholar
  32. 32.
    Zheng SY, Adams M, Mantri RV. An approach to mitigate particle formation on the dilution of a monoclonal antibody drug product in an IV administration fluid. J Pharm Sci. 2016;105(3):1349–50.CrossRefGoogle Scholar
  33. 33.
    Giannos SA, Kraft ER, Zhao ZY, Merkley KH, Cai JY. Formulation stabilization and disaggregation of bevacizumab, ranibizumab and aflibercept in dilute solutions. Pharm Res. 2018;35(4):78.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Preparing BLINCYTO®. Accessed September 22, 2018.
  35. 35.
    ISMP Canada. Managing overfill during preparation and delivery of intravenous medications. ISMP Canada Safety Bull. 2013;13(7):1–5. Accessed March 7, 2019.Google Scholar
  36. 36.
    Syringe pull-back: a stubborn but unsafe drug prep method. 2015. Accessed March 7, 2019.
  37. 37.
  38. 38.
    Rios C, Vialet R, Dosmas C, Loundou A, Michel F. Comparing three methods for dilution accuracy of intravenous preparations. J Perianesth Nurs. 2016;31(2):113–7.CrossRefGoogle Scholar
  39. 39.
    Stucki C, Sautter AM, Wolff A, Fleury-Souverain S, Bonnabry P. Accuracy of preparation of i.v. medication syringes for anesthesiology. Am J Health Syst Pharm. 2013;70(2):137–42.CrossRefGoogle Scholar
  40. 40.
    Wheeler DW, Degnan BA, Sehmi JS, Burnstein RM, Menon DK, Gupta AK. Variability in the concentrations of intravenous drug infusions prepared in a critical care unit. Intensive Care Med. 2008;34(8):1441–7.CrossRefGoogle Scholar
  41. 41.
    Massoomi F, PharmD, FASHP. The evolution of the CSTD. Oncol Safety. 2015;12(2):1.Google Scholar
  42. 42.
    Bee JS, Randolph TW, Carpenter JF, Bishop SM, Dimitrova MN. Effect of surfaces and leachable on the stability of biopharmaceuticals. J Pharm Sci. 2011;100(10):4158–70.CrossRefGoogle Scholar
  43. 43.
    Fujita R, Nagatoishi S, Adachi S, Nishioka H, Ninomiya H, Kaya T, Takai M, Arakawa T, Tsumoto K. Control of protein adsorption to cyclo olefin polymer by the Hofmeister effect. J Pharm Sci. 2019. Accessed March 7, 2019.
  44. 44.
    Pinholt C, Hartvig RA, Medlicott NJ, Jorgensen L. The importance of interfaces in protein drug delivery – why is protein adsorption of interest in pharmaceutical formulations? Expert Opin Drug Deliv. 2011;8(7):949–64.CrossRefGoogle Scholar
  45. 45.
    Chang JY, Xiao NJ, Zhu M, et al. Leachables from saline-contained IV bags can alter therapeutic protein properties. Pharm Res. 2010;27:2402–13.CrossRefGoogle Scholar
  46. 46.
    Mcleod AG, Walker IR, Zheng S, Hayward CPM. Loss of factor VIII activity during storage in PVC containers due to adsorption. Haemophilia. 2000;6(2):89–92.CrossRefGoogle Scholar
  47. 47.
    Sreedhara A, Glover ZK, Piros N, Xiao N, Patel A, Kabakoff B. Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions. J Pharm Sci. 2011;101(1):21–30.CrossRefGoogle Scholar
  48. 48.
    Kumar O, Liu J, Ji J, Cheng W, Wang J, Joshi S, Middaugh CR, Volkin D. Compatibility, physical stability and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags. J Pharm Sci. 2012;101(10):3636–50.CrossRefGoogle Scholar
  49. 49.
    Mahler HC, Senner F, Maeder K, Mueller R. Surface activity of a monoclonal antibody. J Pharm Sci. 2009;98(12):4525–33.CrossRefGoogle Scholar
  50. 50.
    Morar-Mitrica S, Puri M, Beumer Sassi A, Fuller J, Hu P, Crotts G, Nesta D. Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration. MAbs. 2015;7(4):792–803.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Shi S, Hashemi V, Wang SC, Yang J, Yang MM, Semple A, Narasimhan C, Antochshuk V. Overcoming challenges with intravenous administration of an investigational protein therapeutic. J Pharm Sci. 2017;106(12):3465–73.CrossRefGoogle Scholar
  52. 52.
    Werner BP, Winter G. Particle contamination of parenteralia and in-line filtration of proteinaceous drugs. Int J Pharm. 2015;496(2):250–67.CrossRefGoogle Scholar
  53. 53.
    Besheer A. Protein adsorption to in-line filters of intravenous administration sets. J Pharm Sci. 2017;106(10):2959–65.CrossRefGoogle Scholar
  54. 54.
    Pardeshi NN, Qi W, Dahi K, Caplan L, Carpenter JF. Microparticles and nanoparticles delivered in intravenous saline and in an intravenous solution of a therapeutic antibody product. J Pharm Sci. 2017;106(2):511–20.CrossRefGoogle Scholar
  55. 55.
    Liu L, Randolph TW, Carpenter JF. Particles shed from syringe filters and their effects on agitation-induced protein aggregation. J Pharm Sci. 2012;101(8):2952–9.CrossRefGoogle Scholar
  56. 56.
    Product information for trastuzumab emtansine (Kadcyla). Accessed March 7, 2019.
  57. 57.
    Werner BP, Winter G. Expanding bedside Filtrationd-a powerful tool to protect patients from protein aggregates. Usefulness of the final filter of the IV infusion set in intravenous administration of drugs-contamination. J Pharm Sci. 2018;107:2775–88.CrossRefGoogle Scholar
  58. 58.
    Kuramoto K, Shoji T, Nakagawa Y. Usefulness of the final filter of the IV infusion set in intravenous administration of drugs-contamination of injection preparations by insoluble microparticles and its causes. Yakugaku Zasshi. 2006;126:289–95.CrossRefGoogle Scholar
  59. 59.
    Ruzickova K, Cobbing M, Rossi M, Belazzi T. Preventing harm from phthalates, avoiding PVC in hospitals. Accessed March 7, 2019.
  60. 60.
    Food and Drug Administration. Safety assessment of di(2-ethylhexyl) phthalate (DEHP) released from PVC medical devices. 2010. Accessed March 6, 2019.
  61. 61.
    Cheung JK, Sharma M, Dabbara A, Petersen J. The effect of formulation excipients on leachables for iv-administered products. 2012. Accessed March 7, 2019.
  62. 62.
    FDA warns against using Treanda Injection (solution) with closed system transfer devices, adapters, and syringes containing polycarbonate or acrylonitrile-butadiene-styrene; provides list of compatible devices. Accessed Feb 12, 2019.
  63. 63.
    Kiese S, Papppenberger A, Friess W, Mahler HC. Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J Pharm Sci. 2008;97(10):4347–66.CrossRefGoogle Scholar
  64. 64.
    Koepf E, Eisele S, Schroeder R, Brezesinski G, Friess W. Notorious but not understood: how liquid-air interfacial stress triggers protein aggregation. Int J Pharm. 2018;537(1-2):202–12.CrossRefGoogle Scholar
  65. 65.
    Rudiuk S, Cohen-Tannoudji L, Huille S, Tribet C. Importance of the dynamics of adsorption and of a transient interfacial stress on the formation of aggregates of IgG antibodies. Soft Matter. 2012;8(9):2651–61.CrossRefGoogle Scholar
  66. 66.
    Bee JS, Schwartz DK, Trabelsi S, Freund E, Stevenson J, Carpenter JF, Randolph TW. Production of particles of therapeutic proteins at the air–water interface during compression/dilation cycles. Soft Matter. 2012;8(40):10329–35.CrossRefGoogle Scholar
  67. 67.
    Shieh I, Patel AR. Predicting the agitation-induced aggregation of monoclonal antibodies using surface tensiometry. Mol Pharm. 2015;12:3184–93.CrossRefGoogle Scholar
  68. 68.
    Lee HJ, McAuley A, Schilke KF, McGuire J. Molecular origins of surfactant-mediated stabilization of protein drugs. Adv Drug Deliv Rev. 2011;63(13):1160–71.CrossRefGoogle Scholar
  69. 69.
    Patapoff T, Esue O. Polysorbate 20 prevents the precipitation of a monoclonal antibody during shear. Pharm Dev Technol. 2009;14(6):659–64.CrossRefGoogle Scholar
  70. 70.
    Singh SM, Bandi S, Jones DNM, Mallela KMG. Effect of polysorbate 20 and polysorbate 80 on the higher-order structure of a monoclonal antibody and its fab and fc fragments probed using 2d nuclear magnetic resonance spectroscopy. J Pharm Sci. 2017;106(12):3486–98.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Agarkhed M, O’Dell C, Hsieh MC, Zhang J, Goldstein J, Srivastava A. Effect of surfactants on mechanical, thermal, and photostability of a monoclonal antibody. AAPS PharmSciTech. 2018;19(1):79–92.CrossRefGoogle Scholar
  72. 72.
    Wang S, Wu G, Zhang X, Tian Z, Hu T, Dai W, Qian F. Stabilizing two IgG1 monoclonal antibodies by surfactants: balance between aggregation prevention and structure perturbation. Eur J Pharm Biopharm. 2017;114:263–77.CrossRefGoogle Scholar
  73. 73.
    John WM. Microbiological quality of drug products after penetration of the container system for dose preparation prior to patient administration. 2009. Accessed March 7, 2019.
  74. 74.
    Wu HC, Chen TN, Kao SH, Shui HA, Chen WJ, Lin HJ, Chen HM. Isoelectric focusing management: an investigation for salt interference and an algorithm for optimization. J Proteome Res. 2010;9(11):5542–56.CrossRefGoogle Scholar
  75. 75.
    Haybrard J, Simon N, Danel C, Pinçon C, Barthélémy C, Tessier FJ, Décaudin B, Boulanger E, Odou P. Factors generating glucose degradation products in sterile glucose solutions for infusion: statistical relevance determination of their impacts. Sci Rep. 2017;7:11932.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    USP. Dextrose injection. Pharmacopeial Forum. 2004;30(5):1614.Google Scholar
  77. 77.
    Glover ZW, Gennaro L, Yadav S, Demeule B, Wong PY, Sreedhara A. Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration. J Pharm Sci. 2013;102(3):794–812.CrossRefGoogle Scholar
  78. 78.
    Narhi LO, et al. Subvisible (2–100 μm) particle analysis during biotherapeutic drug product development: Part 1, considerations and strategy. J Pharm Sci. 2015;104:1899–908.CrossRefGoogle Scholar
  79. 79.
    Vincent C, et al. Subvisible (2–100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis. Biologicals. 2015;43(6):457–73.CrossRefGoogle Scholar
  80. 80.
    Bardin C, Astier A, Vulto A, Sewell G, Vigneron J, Trittler R, Daouphars M, Paul M, Trojniak M, Pinguet F. Guidelines for the practical stability studies of anticancer drugs: a European consensus conference. Ann Pharm Fr. 2011;69:221–31.CrossRefGoogle Scholar
  81. 81.
    Khandpour RS. Handbook of biomedical instrumentation. New York: McGraw Hill; 2014. Chapter 68, Parenteral infusion devices.Google Scholar
  82. 82.
    Robert AP, James HP. Critical parameters in drug delivery by intravenous infusion. Expert Opin Drug Deliv. 2013;10(8):1095–108.CrossRefGoogle Scholar
  83. 83.
    U.S. Food & Drug Administration. What Is an Infusion Pump? 2017. Accessed March 7, 2019.
  84. 84.
    Thoele K, Piddoubny M, Ednalino R, Terry CL. Optimizing drug delivery of small-volume infusions. J Infus Nurs. 2018;41(2):113–7.CrossRefGoogle Scholar
  85. 85.
    USP <787> Subvisible particulate matter in therapeutic protein injections. USP 41: 6534-6536.Google Scholar
  86. 86.
    Galush WJ, Horst TA. Vented spikes improve delivery from intravenous bags with no air headspace. J Pharm Sci. 2015;104:2397–400.CrossRefGoogle Scholar
  87. 87.
    Naoki Asakawa, The horror of sample adsorption to containers, Shimadzu Corporation, Accessed September 22, 2018.

Copyright information

© American Association of Pharmaceutical Scientists 2020

Authors and Affiliations

  • Supriya Gupta
    • 1
    Email author
  • Amr Alaarg
    • 2
  • Zhen Wu
    • 1
    • 2
  • Xiaofeng Lu
    • 1
    • 2
  • VivekKumar Garripelli
    • 1
    • 2
  • Hanmin Dong
    • 1
    • 2
  • Stephanie Sawilla
    • 3
  • Bhargav Patel
    • 2
  • Rudolf Schroeder
    • 3
  1. 1.Pharmaceutical Development, CMC Biologics, Oncology Early DevelopmentAbbVieRedwood CityUSA
  2. 2.Formulation Development, New Biological EntitiesAbbVie (United States)North ChicagoUSA
  3. 3.Formulation Development, New Biological EntitiesAbbVie Deutschland GmbH & Co. KGLudwigshafenGermany

Personalised recommendations